Brizzi Patrizia, Tonolo Giancarlo, Bertrand Graziano, Carusillo Francesca, Severino Cristiana, Maioli Mario, Malaguarnera Lucia, Musumeci Salvatore
Diabetes Service, Department of Medicine, University of Sassari, Sassari, Italy.
Clin Chem Lab Med. 2004 Feb;42(2):164-70. doi: 10.1515/CCLM.2004.030.
Oxidized low-density lipoproteins (ox-LDLs) and their autoantibodies (OLAB) are involved in the development of atherosclerosis in animal models, but their role in humans is still not clear. For this reason we studied 54 patients with beta-thalassemia major (TM), as a model of chronically low circulating LDLs with a high level of oxidation; 44 patients with primary hypercholesterolemia, as model of chronically high circulating LDLs; 24 type 2 diabetic mellitus patients (T2DM) before and after 3 months of atorvastatin treatment (20 mg/day), as a model of acute changes in circulating LDLs; and 41 normolipidemic subjects as a control group. ox-LDLs were measured by the determination of baseline diene concentration in the plasma LDL lipidic fraction after 12 hours fasting and were expressed as the amount of conjugated dienes/ liter (BDC/I) or BDC/LDL-cholesterol (LDL-C), which indicate respectively LDL oxidation degree and status. OLAB were determined using an enzyme immunoassay and related to LDL oxidation degree (BDC/I). In TM, BDC/I was lower, while BDC/LDL-C was significantly higher, compared to both hypercholesterolemia and normolipidemic subjects. Patients with hypercholesterolemia had higher BDC/I, but lower BDC/LDL-C and OLAB/BDC-I, than normolipidemic subjects. In T2DM patients at diet, BDC/LDL-C and OLAB/BDC-I were lower than in normolipidemic subjects. After 3 months of atorvastatin treatment, BDC/ LDL-C and OLAB/BDC-I ratios increased. When all patients were evaluated together, a significant inverse correlation was evident between OLAB and either LDL or BDC/I. Our findings suggest that a relationship between OLAB titer and oxidation indices (BDC/I and BDC/LDL-C) does exist and we may speculate that an increase in OLAB/BDC-I ratio might be protective against the risk of atherosclerosis.
氧化型低密度脂蛋白（ox-LDLs）及其自身抗体（OLAB）在动物模型的动脉粥样硬化发展过程中发挥作用，但它们在人类中的作用仍不明确。因此，我们研究了54例重型β地中海贫血（TM）患者，作为循环低密度脂蛋白长期处于低水平且氧化程度高的模型；44例原发性高胆固醇血症患者，作为循环低密度脂蛋白长期处于高水平的模型；24例2型糖尿病（T2DM）患者在阿托伐他汀治疗（20毫克/天）3个月前后，作为循环低密度脂蛋白急性变化的模型；以及41例血脂正常的受试者作为对照组。ox-LDLs通过测定空腹12小时后血浆低密度脂蛋白脂质部分的基线二烯浓度来测量，并表示为共轭二烯/升的量（BDC/I）或BDC/低密度脂蛋白胆固醇（LDL-C），它们分别表示低密度脂蛋白的氧化程度和状态。OLAB使用酶免疫测定法测定，并与低密度脂蛋白氧化程度（BDC/I）相关。与高胆固醇血症和血脂正常的受试者相比，TM患者的BDC/I较低，而BDC/LDL-C显著较高。高胆固醇血症患者的BDC/I较高，但BDC/LDL-C和OLAB/BDC-I低于血脂正常的受试者。在饮食控制的T2DM患者中，BDC/LDL-C和OLAB/BDC-I低于血脂正常的受试者。阿托伐他汀治疗3个月后，BDC/LDL-C和OLAB/BDC-I比值增加。当对所有患者进行综合评估时，OLAB与低密度脂蛋白或BDC/I之间存在显著的负相关。我们的研究结果表明，OLAB滴度与氧化指数（BDC/I和BDC/LDL-C）之间确实存在关系，我们可以推测OLAB/BDC-I比值的增加可能对动脉粥样硬化风险具有保护作用。
